Explore

Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays

Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays

Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays
Trendline Trendline
BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments

BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments

BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments
Trendline Trendline
SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine

SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine

SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Berkshire Hathaway Reports 17.7% Increase in Q1 2026 Operating Earnings

Berkshire Hathaway Reports 17.7% Increase in Q1 2026 Operating Earnings

Berkshire Hathaway Reports 17.7% Increase in Q1 2026 Operating Earnings
Trendline Trendline
Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance

Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance

Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance
Trendline Trendline
IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark